Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE To examine in a 3-year brain imaging study the effects of higher vs lower adherence to a Mediterranean-style diet (MeDi) on Alzheimer disease (AD) biomarker changes (brain β-amyloid load via <sup>11</sup>C-Pittsburgh compound B [PiB] PET and neurodegeneration via <sup>18</sup>F-fluorodeoxyglucose [FDG] PET and structural MRI) in midlife. 29653991 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Regional analysis of relevant AD structures revealed reduction in <sup>18</sup>FDG retention in 5XFAD mice in all brain regions analyzed (save cerebellum) compared to WT<sub>5XFAD</sub>. 28729192 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Correction: Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies. 30883613 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE We evaluated the effect of a reduced acquisition time for <sup>18</sup>F-FDG PET studies of Alzheimer dementia (AD) and frontotemporal dementia (FTD) to derive a limit for reductions of acquisition time (improving patient compliance) and administered activity (lowering the radiation dose) with uncompromised diagnostic outcome. 31028167 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Only a limited number of studies using <sup>18</sup>F-FDG-PET in AD mice were carried out so far showing contradictory findings in cerebral FDG uptake. 31058151 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Education-Adjusted Normality Thresholds for FDG-PET in the Diagnosis of Alzheimer Disease. 29870998 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE The model was applied to FDG PET data of Alzheimer's disease (AD) and mild cognitive impairment (MCI) and clinical routine FDG PET data for assessing behavioral abnormality and seizures. 31003928 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE To evaluate longer-term prediction of MCI to AD conversion using 18F-FDG-PET and MRI in a multicenter study. 28922157 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE While the sensitivity of <sup>18</sup>F-FDG PET to detect Alzheimer's disease is high, specificity is low and the additional use of biomarkers for amyloid deposition might be beneficial in some cases. 29512075 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE the evaluation is done on ADNI dataset.The proposed method outperforms other state-of-the-art <sup>18</sup>F-FDG PET-based algorithms for AD vs. NC with an accuracy, a sensitivity and a specificity values of 93.65%, 91.22% and 96.25%, respectively. 31430595 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Thus, the goal of this study was to identify the combination of cerebrospinal fluid (CSF) biomarkers, MRI morphometry, FDG PET metabolism and neuropsychological test scores to that best differentiate between a sample of normal aging subjects and those with MCI and AD from the Alzheimer's Disease Neuroimaging Initiative. 29415470 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE <b>Methods:</b><sup>18</sup>F-FDG PET scans of 544 MCI patients were obtained from the Alzheimer Disease Neuroimaging Initiative database and analyzed. 30389825 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE FDG and rs-fMRI metrics distinguished aMCI/AD from controls according to spatial patterns analogous to those found in stand-alone studies. 29709628 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 GeneticVariation disease BEFREE The multivariate logistic model identified FDG-PET "AD" SPM classification (Expβ = 19.35, 95% C.I. 29387532 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Discriminative performance (prodromal vs Alzheimer's disease dementia) of [<sup>18</sup>F]THK5317 (early-phase SUVr and R<sub>1</sub>) was compared with that of [<sup>11</sup>C]PIB (early-phase SUVr and R<sub>1</sub>) and [<sup>18</sup>F]FDG. 27107028 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 GeneticVariation disease BEFREE In this study, <sup>18</sup>F-FDG PET and clinical assessments were collected in a cohort of 422 individuals [including 130 with AD, 130 with MCI, and 162 healthy controls (HCs)] from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and 44 individuals (including 22 with AD, and 22 HCs) from Huashan Hospital, Shanghai, China. 30956687 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Metabolic Brain Network Analysis of FDG-PET in Alzheimer's Disease Using Kernel-Based Persistent Features. 31234358 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 GeneticVariation disease BEFREE This review aims to help readers understand the role of <sup>18</sup>F-FDG PET/CT imaging in the investigation of cognitive impairment and how the advent of amyloid PET/CT imaging may hold the key to radically changing management of the most common form of dementia - Alzheimer's disease. 30982329 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE SPM analysis in AD patients showed a significant negative correlation between [<sup>18</sup>F] FBB and [<sup>18</sup>F] FDG uptake in temporal and parietal lobes bilaterally. 29404839 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE We assessed ninety-six subjects (27 cognitively normal, 49 mild cognitive impairment, and 20 AD dementia) who underwent [<sup>18</sup>F]FDG and [<sup>18</sup>F]Florbetapir positron emission tomography (PET) as well as magnetic resonance imaging (MRI) with diffusion tensor imaging. 30414086 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE <sup>18</sup>F-FDG PET, the early phases and the delivery rate of <sup>18</sup>F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against <sup>15</sup>O-H<sub>2</sub>O PET. 31405824 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Consecutive one-hundred and forty-three subjects with AD and 181 normal subjects who underwent both 18F-FDG PET and 18F-florbetapir (AV-45) PET at baseline were included to this study from the database of Alzheimer's disease neuroimaging initiative (ADNI). 27334941 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE SNAP subjects show milder impairment of brain [<sup>18</sup>F] FDG uptake as compared to AD. 31201430 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 Biomarker disease BEFREE Based on different patterns of altered cerebral glucose metabolism, 18F-FDG PET was clinically used for differential diagnosis of AD and Frontotemporal dementia (FTD). 28671127 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 GeneticVariation disease BEFREE We included 38 patients with mild-to-moderate AD (mean age 67 ± 7 years, mean MMSE score 24 ± 4, mean years of education 14 ± 4; 20 men, 18 women) in whom a [<sup>18</sup>F]AV-1451 scan (a measure of tau pathology) and an [<sup>18</sup>F]FDG scan (a measure of neuronal function) were available. 31183635 2019